Clinical trials: sponsored by Merck Sharp & Dohme LLC
Mature B-cell Neoplasms
A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of nemtabrutinib in Japanese participants with mature B-cell neoplasms.
- Trial name
- NCT05673460
- Testing
- Nemtabrutinib
- Where
- 7 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
This clinical trial will evaluate a new combination of pembrolizumab, HPV-16 E6/E7 specific therapeutic vaccination (ISA101b) and cisplatin-based chemoradiotherapy for patients with newly diagnosed, local-regionally advanced…
- Trial name
- NCT04369937
- Testing
- IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dan Zandberg
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Non Small Cell Lung Cancer
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours.
- Trial name
- HyPeR (NCT02998567)
- Testing
- Guadecitabine, Pembrolizumab, ASTX727
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer Metastatic, Neuroendocrine Tumors
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to…
- Trial name
- PLANE-PC (NCT04848337)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Michigan Rogel Cancer Center
RSV Infection
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
- Trial name
- SMART (NCT04938830)
- Testing
- Clesrovimab, Palivizumab
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 1,003 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Cancer
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the vagina (vaginal cuff brachytherapy) followed by three cycles of…
- Trial name
- FIERCE (NCT03932409)
- Testing
- Pembrolizumab, Vaginal cuff brachytherapy (VCB), Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Oklahoma
Carcinoma, Squamous Cell, Skin Neoplasms
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC).
- Trial name
- INTerpath-007 (NCT06295809)
- Testing
- Pembrolizumab, Intismeran autogene, Surgery
- Where
- 106 sites in United States, Argentina and 18 more
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)
Researchers want to learn about calderasib when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body over time when given with…
- Trial name
- NCT07222098
- Testing
- Rosuvastatin, Metformin, Calderasib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervix Cancer, Cervical Cancer
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
The main purpose of this study is to gather information about an investigational drug combination, Lenvatinib in combination with pembrolizumab, that may help to treat cervical cancers.
- Trial name
- NCT06266338
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Neoplasia
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia
The researchers involved in this new study are interested in whether giving a HPV vaccine to women at the same time as conisation can lead to a greater rate of HPV clearance compared to conisation on its own, and a result reduce…
- Trial name
- NOVEL (NCT03979014)
- Testing
- Gardasill 9™ vaccine
- Where
- 13 sites in Finland, Sweden and 1 more
- Volunteers
- 1,099 people
- Sponsor
- Imperial College London
HIV Preexposure Prophylaxis
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who…
- Trial name
- Impower-024 (NCT04652700)
- Testing
- ISL, FTC/TDF, FTC/TAF
- Where
- 25 sites in United States, Brazil and 5 more
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal…
- Conditions
- Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- PROTA (NCT05271318)
- Testing
- TILT-123, pembrolizumab, pegylated liposomal doxorubicin
- Where
- 3 sites in United States, Finland
- Volunteers
- 29 people
- Sponsor
- TILT Biotherapeutics Ltd.
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
- Trial name
- NCT04586231
- Testing
- Belzutifan, Lenvatinib, Cabozantinib
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 747 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT04199104
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 152 sites in United States, Australia and 17 more
- Volunteers
- 511 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent…
- Trial name
- NCT05173987
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Where
- 194 sites in United States, Australia and 25 more
- Volunteers
- 280 people
- Sponsor
- Merck Sharp & Dohme LLC
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks.
- Trial name
- NCT05956041
- Testing
- Pembrolizumab, Mogamulizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan Rogel Cancer Center
Vulvar Cancer, Vulvar Squamous Cell Carcinoma
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma.
- Trial name
- NCT04430699
- Testing
- Cisplatin, Pembrolizumab, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
NSCLC, Stage I
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm.
- Trial name
- NCT04317534
- Testing
- Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 244 people
- Sponsor
- Greg Durm, MD
Cancer of Unknown Primary Site
Trial of Pembrolizumab in Cancer of Unknown Primary
Abbreviated Title : CUPem Clinical Indication : A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary Trial Type : Single Arm, non-randomised; Two-stage; Hypothesis generating Type of control : None Route of…
- Trial name
- CUPem (NCT03752333)
- Testing
- Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Imperial College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.